return equiti ttm
strong balanc sheet head
take stock rel flat today despit earn miss head
quarter gradual rise expect organ growth slightli
estim adjust ep line model believ investor
look past fourth-quart earn miss potenti risk full-year guidanc
coronaviru see stand-alon busi grew organ revenu
quarter expand oper margin basi point constant currenc
addit believ capabl gener nearli billion free cash flow
next three year assum convers ratio balanc sheet
alreadi slightli time leverag expect signific proport capit
alloc acquisit share repurchas dividend maintain outperform
result adjust ep increas year-over-year consensu
estim product recal european healthcar busi neg
impact adjust ep earn growth driven organ revenu growth
point declin volum point increas price adjust oper
margin expans basi point cc total revenu billion
consensu billion
consolid organ revenu increas fourth quarter driven
approxim point declin volum point increas price
estim organ growth exclud impact upstream energi busi
soon combin organ revenu growth would increas
segment organ revenu growth industri segment institut
organ revenu declin energi busi
free increas billion mark second year double-
digit growth continu make invest digit technolog product
innov exclud voluntari pension contribut million free cash flow
would increas convers rate free cash flow adjust net
incom estim billion free cash flow compani stock
current trade free cash flow yield
guidanc manag expect sale growth acceler despit
expect slightli slower global growth rel incorpor two
point price slightli lower ep guidanc rang impli
growth exclud impact pension contribut coronaviru
foreign currenc guidanc impli adjust ep growth
manag incorpor impact coronaviru beyond first quarter
believ risk guid result adjust
ep estim slightli guidanc rang acknowledg
increment headwind could off-set aggress share buy-back
lead global provid chemical-bas program solut institut industri energi
end-market sale gener outsid unit state
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
forecast lower forecast full-year revenu growth adjust ep
primarili due lower-than-expect sale energi continu foreign-curr headwind slightli
softer first-half growth certain industri end-market due among thing coronaviru
foreign currenc revenu gener outsid unit state cost estim cog sale relat raw materi primarili petroleum base cyclic end-market compani primari end-market vulner macroeconom condit risk includ difficulti attract target compani integr challeng potenti overpay target compani de-regul mani busi subject govern regul includ public health wastewat discharg oil ga etc segment risk valuationfourth quarter earningsseg revenueglob organ fx paper textil life scienc organ fx institut specialti hc oper incomeglob organ om expans organ om expans risksvalu conclus share trade market premium compani histor averag premium valuat share held last month expect gener double-digit earn growth next sever year expect share appreci line earn growth high recur revenu base attract valu proposit sticki custom relationship also believ share lower risk profil rel market maintain outperform ratingglob organ fx upstream lower downstream organ fx pest colloid organ om expans organ om expans william blair
figur million except per-shar item
good sold
incom avail common
sale
good sold
good sold
sourc compani data william blair estim
million except per share
percentag total sale
figur million
sourc compani report william blair estim
